Balaxi Pharmaceuticals Ltd. engages in the exportation of pharmaceutical, hardware, and FMCG products. The company is headquartered in Hyderabad, Telangana and currently employs 51 full-time employees. The company went IPO on 2015-11-30. The firm is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. The company has a portfolio across multiple therapeutic segments, stock & sell models, and supplying branded and generic medicines. The firm is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its consumer products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.